Brief: Deciphera Pharmaceuticals Looks To Initiate Phase 2 Proof-Of-Concept Study Of Vimseltinib For Treating Chronic Graft Versus Host Disease

Deciphera Pharmaceuticals

08/01/2024 13:30

Jan 8 (Reuters) - Deciphera Pharmaceuticals Inc
 DCPH.O :
    * DECIPHERA PHARMACEUTICALS- SEES TO INITIATE PHASE 2
PROOF-OF-CONCEPT STUDY OF VIMSELTINIB FOR TREATING CHRONIC GRAFT
VERSUS HOST DISEASE IN Q4 2024
    * DECIPHERA PHARMACEUTICALS- PRELIMINARY UNAUDITED CASH,
CASH
EQUIVALENTS, MARKETABLE SECURITIES OF APPROXIMATELY $352.0
MILLION AS OF DEC 31, 2023
    * DECIPHERA PHARMACEUTICALS INC - EXPECTS TO SUBMIT
VIMSELTINIB
NEW DRUG APPLICATION (NDA) IN Q2 OF 2024
    * DECIPHERA PHARMACEUTICALS INC - CASH RUNWAY EXTENDED INTO
SECOND
HALF OF 2026

Source text for Eikon:  ID:nBw8XjDDya 
Further company coverage:  DCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))